Kurse werden geladen...
Prognose
Kaufen | 4 |
Halten | 3 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.» Mehr auf globenewswire.com
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.» Mehr auf prnewswire.com
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL).» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | 100,00% |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | 0,00 | 100,00% |
EBITDA | −3,06 Mio | 72,08% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 5,52 Mio€ |
Anzahl Aktien | 3,26 Mio |
52 Wochen-Hoch/Tief | 13,00€ - 1,47€ |
Dividenden | Nein |
Beta | 1,97 |
KGV (PE Ratio) | −0,93 |
KGWV (PEG Ratio) | −0,03 |
KBV (PB Ratio) | 1,63 |
KUV (PS Ratio) | 2.690,09 |
Unternehmensprofil
Name | Soligenix Aktie |
CEO | Dr. Christopher J. Schaber Ph.D. |
Mitarbeiter | 14 |
Assets entdecken
Shareholder von Soligenix Aktie investieren auch in folgende Assets